☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Head and Neck
GSK Discontinues the P-II Trials of Feladilimab for Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
April 16, 2021
PureTech’s LYT-200 Gains the US FDA’s Fast Track Designation for Treating Head and Neck Cancers
April 11, 2024
Rapt Therapeutics Reports the P-II Study Results of Tivumecirnon Plus Keytruda for Treating Head and Neck Cancer
April 10, 2024
PDS Biotech Reports Updated Interim Results from the P-II Trial (VERSATILE-002) Results of PDS0101 + Keytruda for Head and Neck Ca...
October 4, 2023
Merck and Eisai Discontinue P-III Trial (LEAP-010) of Keytruda + Lenvima for Recurrent or Metastatic Head and Neck Squamous Cell C...
August 28, 2023
Ultimovacs Reports the Completion of Patient Enrolment in P-II Study (FOCUS) of UV1 for Head and Neck Cancer
August 3, 2023
MEI Pharma Signs a Definitive Merger Agreement with Infinity Pharmaceuticals to Advance Three Clinical Oncology Candidates
February 24, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.